BriaCell partners with MSK accelerator for breast cancer therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
October 21, 2025 7:30 AM EDTCollaboration with MSKs Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+ platform, which includes Bria-BRES+ for breast cancer
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT)Â (BriaCell or the Company), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Centers (MSKs)... More



